[Clinical outcomes of trimetazidine in patients with acute ST segment elevation myocardial infarction without ST segment resolution after primary percutaneous coronary intervention].
Zhonghua Yi Xue Za Zhi
; 89(20): 1399-401, 2009 May 26.
Article
en Zh
| MEDLINE
| ID: mdl-19671333
ABSTRACT
OBJECTIVE:
To evaluate prospectively the clinical outcomes of trimetazidine (TMZ) in patients with acute ST segment elevation myocardial infarction (STEMI) without ST segment resolution (STR) after primary percutaneous coronary intervention (PPCI).METHODS:
From August 2005 to October 2007, 138 acute STEMI patients without STR after PPCI were randomly assigned to either with TMZ therapy (TMZ group, n = 70) or without TMZ (control group, n = 68). Baseline characteristics, PCI features and clinical outcomes during hospitalization were compared between the two groups. Left ventricular ejection fraction (LVEF) and major adverse cardiac events (MACE, including death, re-infarction and target vessel revascularization) at Days 30 and 180 after discharge were also compared.RESULTS:
The baseline clinical characteristics were comparable between the two groups. There was no significant difference in MACE rates at Days 30 and 180 between the two groups (10/70 vs 11/68, P > 0.05; 15/70 vs 13/68, P > 0.05, respectively). The LVEFs of TMZ group at Days 30 and 180 were significantly superior to the control group (51 +/- 8)% vs (45 +/- 7)%, P < 0.05; (56 +/- 7)% vs (49 +/- 8)%, P < 0.05, respectively).CONCLUSION:
Use of TMZ for patients with acute STEMI without STR after primary PCI can improve the left ventricular function at Days 30 and 180.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Trimetazidina
/
Vasodilatadores
/
Infarto del Miocardio
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
Idioma:
Zh
Revista:
Zhonghua Yi Xue Za Zhi
Año:
2009
Tipo del documento:
Article